Home›Trial›NCT07361562
🔬NCT07361562Phase 1RECRUITING

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Study Summary

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.

Conditions
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene AmplificationHER2 OverexpressionNon-Small Cell Lung CancerHER2
Interventions / Drugs
CGT4255
View on ClinicalTrials.gov ↗
Sponsor
COGT
Cogent Biosciences
Precision Medicine
D45/100
Study Details
Enrollment100 participants
Primary Completion—
Lead SponsorCogent Biosciences, Inc.
Data Retrieved2026-04-11 04:10:18.672993+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.